Last reviewed · How we verify
Flozin
Flozin is a Small molecule drug developed by Collegium Medicum w Bydgoszczy. It is currently in Phase 2 development. Also known as: Empagliflozin, Jardiance, Dapagliflozin, Forxiga.
Flozin, also known as dapagliflozin, is a medication that inhibits sodium/glucose cotransporter 2 (SGLT2), which leads to the inhibition of glucose reabsorption in the kidney and a lowering of blood sugar. It has been studied in various clinical trials for conditions such as Heart Failure, Coronary Artery Disease, and Acute Kidney Injury.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Flozin |
|---|---|
| Also known as | Empagliflozin, Jardiance, Dapagliflozin, Forxiga |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
- Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flozin CI brief — competitive landscape report
- Flozin updates RSS · CI watch RSS
- Collegium Medicum w Bydgoszczy portfolio CI
Frequently asked questions about Flozin
What is Flozin?
Who makes Flozin?
Is Flozin also known as anything else?
What development phase is Flozin in?
Related
- Manufacturer: Collegium Medicum w Bydgoszczy — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Empagliflozin, Jardiance, Dapagliflozin, Forxiga
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing